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Livia Sanna1, Amanda L Stuart2, Julie A Pasco2,4, Mark A Kotowicz2,4, Michael Berk2,3,6,7, Paolo Girardi1,
Sharon L Brennan2,4,5 and Lana J Williams2,3*Abstract
Background: The mind-body nexus has been a topic of growing interest. Further data are however required to
understand the specific relationship between mood and anxiety disorders and individual physical health conditions,
and to verify whether these psychiatric disorders are linked to overall medical burden.
Methods: This study examined data collected from 942 men, 20 to 97 years old, participating in the Geelong
Osteoporosis Study. A lifetime history of mood and anxiety disorders was identified using the Structured Clinical
Interview for DSM-IV-TR Research Version, Non-patient edition (SCID-I/NP). The presence of medical conditions
(lifetime) was self-reported and confirmed by medical records, medication use or clinical data. Anthropometric
measurements and socioeconomic status (SES) were determined and information on medication use and lifestyle
was obtained via questionnaire. Logistic regression models were used to test the associations.
Results: After adjustment for age, socioeconomic status, and health risk factors (body mass index, physical activity
and smoking), mood disorders were associated with gastro oesophageal reflux disease (GORD), recurrent
headaches, blackouts and/or epilepsy, liver disorders and pulmonary disease in older people, whilst anxiety
disorders were significantly associated with thyroid, GORD and other gastrointestinal disorders, and psoriasis.
Increased odds of high medical burden were associated with both mood and anxiety disorders.
Conclusions: Our study provides further population-based evidence supporting the link between mental and
physical illness in men. Understanding these associations is not only necessary for individual management, but also
to inform the delivery of health promotion messages and health care.
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For centuries, it has been hypothesised and debated that
a mind-body interaction exists. Over time, an evidence
base has grown to support this notion, yet an incomplete
understanding prevails [1,2]. Rates of depression and
anxiety are generally higher among the physically ill than
in the general population; however, results vary accor-
ding to the type and severity of the chronic disease and
methods of ascertainment [3,4].
Within clinical samples, patients with depression have
been found to have a significantly higher number of* Correspondence: lanaw@barwonhealth.org.au
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reproduction in any medium, provided the orsomatic symptoms [5] and a higher risk of chronic
diseases [6-8], such as coronary heart disease [9,10], con-
gestive heart failure [11], stroke and dementia [12], dia-
betes [13,14], gastro oesophageal reflux disease (GORD)
[15], osteoarthritis and rheumatoid arthritis [16], pso-
riasis [17], cancer [18], neurological disorders [19], pul-
monary disease [20], liver disease [21], thyroid disorders
[22] and asthma [23,24], as well as non-specific syn-
dromes such as obesity [25], anaemia [26], renal dys-
function [27], chronic fatigue syndrome [28], chronic
headaches [24], and chronic pain [29]. The strength of
the association as well as the extent of the evidence va-
ries for each medical condition.
Similarly, anxiety disxorders, have been shown to be
related to several medical conditions, such as cardiovas-
cular disease [30], cancer [18], obesity [31] and othertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gastrointestinal problems [34], GORD [15], thyroid dis-
orders [35], psoriasis [17] and a higher number of me-
dical symptoms [36]. In addition, as recently reviewed by
Culpepper and colleagues, migraine and chronic pain,
diabetes, peptic ulcer, arthritis and pulmonary disease
are also associated [2].
The co-occurrence of mood or anxiety disorders and
physical illness worsens the impact of symptom burden
[36], impacts disease course, links to the deteriorating
patient’s health status and functioning [7,37], affects
medication response and treatment adherence [38], and
increases the risk of complications [39] and even death
[37]. Moreover, the comorbidity between mental and
physical illness is relevant in terms of role impairment
and work performance [24], as well as quality of life and
health service use and costs [40].
The causal pathway between comorbid mental and
physical illness is complex and remains unclear. It has
been suggested that the bi-directionality of this relation-
ship may involve several mechanisms [41,42] including
biological (for example, increased pro-inflammatory cy-
tokines, hypothalamic-pituitary axis deregulation, auto-
nomic nervous system dysfunction, serotonin depletion,
metabolic, immune and endocrine changes) [43], psycho-
logical (for example, behavioural, psychodynamic and cog-
nitive factors) [44] and social (for example, impaired social
support, loneliness, and social disengagement) [45]. Fur-
thermore, psychotropic medication use has been linked to
a higher incidence of an array of health outcomes, inclu-
ding diabetes, falls and bleeding, osteoporosis, and sudden
cardiac death [46-48].
Enhancing the quality of care for those with mental ill-
ness not only can improve mood and anxiety symptoms,
but also physical health in patients with comorbid men-
tal and physical illness [49]. Furthermore, treatment for
these disorders may influence each other [50]. Thus, es-
timating the prevalence and understanding the asso-
ciation between mood and anxiety disorders and physical
illness is important in order to make more accurate diag-
noses and to provide integrated and effective treatment,
with regard to syndrome reciprocal influences and medi-
cation interactions. Given these data, we aimed to describe
the relationship between comorbid mental and physical
illness in a large, representative sample of men residing in
Australia, utilising structured clinical interviews, medical
records, and clinical and self-reported data collected as
part of the Geelong Osteoporosis Study (GOS) [51].
Methods
Participants
Data were derived from the GOS male cohort, a study
originally designed to investigate the epidemiology of
osteoporosis in Australia. Originally, an age-stratified,population-based sample of adult men (n = 1,540; re-
sponse 67%, 20 to 97 years old) was randomly-selected
from the Australian Electoral Commission (AEC) rolls for
the Barwon Statistical Division between 2001 and 2006.
The Barwon Statistical Division is situated in South-
Eastern Australia, comprising both rural and urban com-
munities. Further details of the study have been published
elsewhere [51].
Of those invited to participate in the five-year follow-
up study (n = 1,540), 141 had died, 41 had left the study
region, 16 were unable to provide written informed con-
sent, 139 were not able to be contacted and 225 declined
to participate resulting in 978 participants (81% of the
eligible baseline sample). For this analyses, those who
did not undergo psychiatric assessment (n = 17) or pro-
vide medical information (n = 19) were excluded, re-
sulting in a final sample of 942 eligible men. This study
was approved by the Barwon Health Human Research
Ethics Committee and written informed consent was ob-
tained from all participants.
Assessments
Psychiatric measures
The Structured Clinical Interview for the Diagnostic and
Statistical Manual of Mental Disorders, 4th edition, text
revision (DSM-IV-TR) Research Version, Non-patient
edition (SCID-I/NP) [52] was used to identify those who
had ever experienced a mood disorder, including major
depressive disorder, bipolar disorder (types I and II), dys-
thymia, minor depression, mood disorder due to general
medical condition (GMC) and substance-induced mood
disorder; and/or an anxiety disorder including panic
disorder, agoraphobia, social phobia, specific phobia, ob-
sessive compulsive disorder, generalised anxiety disorder,
anxiety disorder due to a medical condition, substance-
induced anxiety disorder or anxiety disorder not otherwise
specified. All interviews were conducted by personnel
with qualifications in psychology, who were trained using
live and videotaped interviews under the supervision of a
psychiatrist.
Clinical measures
Height was measured to the nearest 0.1 cm using a wall-
mounted stadiometer and body weight was measured to
the nearest 0.1 kg using electronic scales. Body mass index
(BMI; kg/m2) was calculated from these measurements.
Lumbar spine and femoral neck bone mineral density
(BMD) was measured by dual energy X-ray absorptiome-
try (DXA) using GE Lunar Prodigy (Prodigy GE Lunar
Madison, WI, USA). Long term stability of the machine
was tested three times weekly by scanning an anthro-
pomorphic phantom (Hologic). Low bone mass was
classified according to the World Health Organisation
definition; one or more standard deviations below the
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posterior-anterior projection) [53].
Medical conditions
The presence of medical conditions (lifetime) was self-
reported and confirmed by medical records, medication
use or clinical data, where possible. Musculoskeletal dis-
ease was defined by low BMD or self-reported osteoarth-
ritis, ankylosing spondylitis, psoriatic arthritis, rheumatoid
arthritis, muscle disease or weakness, low trauma fracture,
or self-reported or medicated gout (agents used in gout or
hyperuricaemia). Thyroid disorders included self-reported
or medicated (thyroid hormones and anti-thyroid
agents) hyperthyroidism, hypothyroidism, Graves’ dis-
ease, Hashimoto’s disease, thyroiditis and other unspeci-
fied thyroid conditions. Metabolic risk factors included
a diagnosis of diabetes, defined by self-report or current
medication use (oral hypoglycaemic agents and insulin
preparations), obesity defined by a BMI >30 kg/m2 [54],
self-reported or medicated hypercholesterolemia (use of
cholesterol-lowering agents) and hypertension. Hyper-
tension was characterised by a combination of self-
report and current medication use (antihypertensive,
beta-adrenergic blocking agents and diuretics) or a
systolic blood pressure of >140 mmHg or diastolic blood
pressure of >90 mmHg. Diagnosis of GORD was based on
self-report as were gastrointestinal diseases which include
peptic ulcer, chronic gastritis and causes of malabsorption,
such as pancreatitis, gastric surgery, chronic diarrhoea, ir-
ritable bowel syndrome, inflammatory bowel syndrome
and coeliac disease. Cardiovascular disease was defined by
a diagnosis of hypertension (as detailed above) or a com-
bination of self-reported or medicated (beta-adrenergic
blocking agents, diuretics, anti-arrhythmic, anti-angina,
cardiac inotropic agents, adrenergic stimulants, other car-
diovascular agents) stroke, transient ischaemic accident
(TIA), ischaemic cardiomyopathy, arrhythmia and valve
and vascular diseases. Syncope and seizures included
self-reported epilepsy, blackouts, fainting and dizzy spells.
Self-reported migraine and other recurrent headaches
were grouped together. Lifetime pulmonary disease in-
cluded self-reported asthma, emphysema and chronic
bronchitis. Psoriasis was defined by self-report. Liver dis-
ease diagnosis, including fatty liver, hepatitis, cirrhosis and
liver failure, was also based on self-report. Cancer was de-
fined as any malignant tumour including non-melanoma
skin cancer. High medical burden was classified as a diag-
nosis of three or more conditions listed above.
Other measures
Smoking status, medication use and physical activity
level were obtained by self-report [51]. Reported medica-
tion use was cross-referenced with the participants’ list
of medications or containers and was considered currentif the participants reported use at the time of assessment.
Men were classified as active if they participated in light
to vigorous activity on a regular basis. Alcohol consump-
tion (average grams consumed daily over a 12 month
period) was determined by a validated food frequency
questionnaire [55]. Tobacco smoking was documented
and grouped as current or not. In order to determine
socioeconomic status (SES), residential addresses were
matched to the corresponding Australian Bureau of Statis-
tics (ABS) Census Collection District (CCD). ABS soft-
ware was used to determine the Socio-Economic Index
for Areas (SEIFA) from the 2006 ABS Census data. SEIFA
values summarize the characteristics of subjects within an
area, thereby providing a single measure to rank the level
of disadvantage at the area level, not of the individual sub-
ject. SEIFA values indicate the level of advantage or dis-
advantage within each CCD, small geographic areas that
incorporate approximately 250 houses [56]. These values
inform the Index of Relative Socioeconomic Advantage/
Disadvantage (IRSAD), which accounts for various socio-
economic parameters including high and low income,
educational attainment ranging from no qualifications to a
tertiary degree or higher, the type of occupation from un-
skilled employment to professional positions, and some
measure of wealth (such as owning a car, or number of
bedrooms in a dwelling). The relative SES of participants
was ascertained by categorizing the sample into quintiles
based on cutpoints for the study region [57-59].
Statistical analysis
Differences in characteristics between those with and
without mood and anxiety disorders were compared using
chi-square analyses for discrete variables and Mann–
Whitney for non-parametric continuous variables. Logistic
regression was used to calculate odds ratios (OR) with
95% confidence interval (95% CI) of lifetime medical con-
ditions for those with lifetime mood/anxiety disorders in
comparison to those with no mood/anxiety disorder.
Models were adjusted for age (model I) and then for age,
BMI, SES, physical activity, alcohol consumption and
smoking status (model II). Interactions between exposure
variables were examined. Each analysis was performed
with and without participants with mood disorders due to
GMC; no differences in outcome were detected, therefore,
those with mood disorder due to GMC were included in
all analyses. Values of P <0.05 were accepted as sig-
nificant (including interaction terms). Statistical ana-
lyses were performed using Minitab (version 16; Minitab,
State College, PA, USA).
Results
A total of 160 men (17%) had a lifetime history of mood
disorder, of which 139 (86.9%) were identified with
major depressive disorder, 10 (6.3%) dysthymia, 9 (5.6%)
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mood disorder due to a GMC and 2 (1.3%) substance in-
duced mood disorder. Of the 60 participants (12.2%)
with a history of anxiety disorder, 23 (38.3%) met criteria
for panic disorder, 15 (25%) post-traumatic stress dis-
order, 7 (11.7%) specific phobia, 6 (10%) social phobia, 5
(8.3%) generalized anxiety disorder, 5 (8.3%) obsessive
compulsive disorder and 3 (5%) anxiety disorder not
otherwise specified. Participants with a history of mood
or anxiety disorder were younger than those without;
otherwise the groups were similar (Table 1).
Mood disorder
After adjustments for age, mood disorder was associated
with increased odds of GORD (OR 2.41, 95% CI 1.48 to
3.00, P = 0.027), recurrent headaches (OR 2.46, 95% CI




Number = 942 Number = 160
Age at interview (years) 59.3 (45.7, 73.2) 52.8 (42.6, 64.4





153 (16.2%) 24 (15.0%)
Quintile 2 189 (20.1%) 27 (16.9%)
Quintile 3 182 (19.3%) 29 (18.1%)
Quintile 4 202 (21.4%) 37 (23.1%)
Quintile 5 216 (22.9%) 43 (26.9%)
Physically active 674 (71.9%) 108 (67.5%)
Smokers (current) 105 (11.2%) 23 (14.5%)
Alcohol consumption (g/day) 12.4 (2.2, 28.8) 17.3 (2.0, 34.3)
Musculoskeletal disease 706 (77.0%) 123 (79.4%)
Thyroid disorders 21 (2.2%) 4 (2.5%)
Metabolic risk factors 665 (74.3%) 107 (72.8%)
GORD 124 (13.2%) 29 (18.1%)
Gastrointestinal disorders 164 (17.4%) 31 (19.4%)
Recurrent headaches 50 (5.3%) 15 (9.4%)
Syncope and seizures 157 (16.7%) 37 (23.1%)
Cardiovascular disease 598 (68.5%) 91 (65.5%)
Pulmonary disease All 178 (18.9%) -
<60 years old 90/478 (18.8%) 19/109 (17.4%
≥60 years old 88/464 (19.0%) 18/51 (35.3%)
Liver disorders 55 (5.8%) 16 (10%)
Cancer 162 (17.2%) 20 (12.5%)
Psoriasis 41 (4.3%) 9 (5.6%)
High medical burden 548 (62.2%) 90 (62.9%)
Values are given as median (interquartile range) or number (%). Missing data: BMI,
musculoskeletal disease, number = 25; metabolic risk factors, number = 47; cardiov
gastro oesophageal reflux disease; IRSAD, Index of Relative Socioeconomic Advanta95% CI 1.31 to 3.09, P = 0.002) and liver disorders (OR
2.41, 95% CI 1.40 to 4.98, P = 0.003). Furthermore, a his-
tory of mood disorder was associated with increased
odds of high medical burden (age-adjusted OR 1.80, 95%
CI 1.16 to 2.77, P = 0.008). Mood disorders tended to be
associated with musculoskeletal disease (OR 1.43, 95%
CI 0.93 to 2.21, P = 0.104) and gastrointestinal disorders
(OR 1.47, 95% CI 0.93 to 2.30, P = 0.096). Age was an ef-
fect modifier in the association between mood disorders
and pulmonary disease. Among older men (≥60 years), a
lifetime history of mood disorder was associated with in-
creased odds of pulmonary disease (age-adjusted OR
2.75, 95% CI 1.45 to 5.21, P = 0.002); no association was
detected for those younger than 60 years (P >0.05). These
relationships remained significant after further adjustment
for BMI, SES, physical activity, alcohol consumption and
smoking status (Table 2). No association was observedithout lifetime history of mood disorder and anxiety
ood disorder Anxiety disorder
No P Yes No P
Number = 782 Number = 60 Number = 882
) 60.9 (46.9, 75.4) <0.001 56.2 (41.1, 64.3) 59.9 (46.0, 74.0) 0.013
) 27.1 (24.8, 29.8) 0.671 27.7 (25.1, 30.3) 27.1 (24.6, 29.6) 0.257
129 (16.5%) 0.581 6 (10.0%) 147 (16.7%) 0.147
162 (20.7%) 12 (20.0%) 177 (20.1%)
153 (19.6%) 8 (13.3%) 174 (19.7%)
165 (21.1%) 13 (21.7%) 189 (21.4%)
173 (22.1%) 21 (35.0%) 195 (22.1%)
566 (72.8%) 0.179 46 (76.7%) 628 (71.5%) 0.392
82 (10.5%) 0.153 10 (16.7%) 95 (10.8%) 0.166
11.9 (2.2, 28.3) 0.156 20.3 (2.8, 28.7) 12.0 (2.8, 28.7) 0.179
583 (76.5%) 0.443 47 (79.7%) 659 (76.8%) 0.614
17 (2.2%) 0.799 4 (6.7%) 17 (1.9%) 0.016
558 (74.6%) 0.646 46 (79.3%) 619 (74.0%) 0.367
95 (12.1%) 0.042 16 (26.7%) 108 (12.2%) 0.001
133 (17.0%) 0.472 16 (26.7%) 148 (16.8%) 0.051
35 (4.5%) 0.012 2 (3.3%) 48 (5.4%) 0.481
120 (15.4%) 0.016 12 (20.0%) 145 (16.4%) 0.474
507 (69.1%) 0.401 34 (63.0%) 564 (68.9%) 0.366
- 11 (18.3%) 167 (18.9%) 0.908
) 71/369 (19.2%) 0.671 - - -
70/416 (17%) 0.002 - - -
39 (5%) 0.014 3 (5.0%) 52 (5.9%) 0.775
142 (18.2%) 0.084 8 (13.3%) 154 (17.5%) 0.412
32 (4.1%) 0.387 5 (8.3%) 36 (4.1%) 0.118
458 (62.1%) 0.843 40 (70.2%) 508 (61.7%) 0.199
number = 28; physically active, number = 4; smokers, number = 5;
ascular disease, number = 69; high medical burden, number = 61. GORD,
ge/Disadvantage.
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risk factors, cardiovascular disease, cancer and psoriasis.Anxiety disorder
After adjustment for age, anxiety disorder was associated
with increased likelihood of thyroid disease (OR 5.29,
95% CI 1.63 to 7.14, P = 0.005), GORD (OR 3.84, 95% CI
2.01 to 7.33, P <0.001), gastrointestinal disease (OR 2.22,
95% CI 1.20 to 4.10, P = 0.011) and high medical burden
(OR 2.82, 95% CI 1.43 to 5.53, P = 0.003). Anxiety
disorder also tended to be associated with metabolic
risk factors (OR 1.92, 95% CI 0.96 to 3.83, P = 0.066). Fur-
ther adjustment for BMI, SES, physical activity, alcohol
consumption and smoking status did not affect theseTable 2 Age-adjusted (model I) and fully-adjusted (model II) o
history of mood and anxiety disorders
Mood
Model Odds ratio 9
Musculoskeletal disease I 1.43 (0.9
II 1.47 (0.9
Thyroid disorders I 1.64 (0.5
II 1.81 (0.5
Metabolic risk factors I 1.30 (0.8
IIa 1.29 (0.8
GORD I 2.41 (1.4
II 2.67 (1.6
Gastrointestinal disorders I 1.47 (0.9
II 1.46 (0.9
Recurrent headaches I 2.46 (1.2
II 2.53 (1.3
Syncope and seizures I 2.01 (1.3
II 2.01 (1.2
Cardiovascular disease I 1.27 (0.8
II 1.28 (0.8
Pulmonary disease All I -
II -
<60 years old I 0.90 (0.5
II 1.01 (0.5
≥60 years old I 2.75 (1.4
II 2.65 (1.3
Liver disorders I 2.64 (1.4
II 3.03 (1.5
Cancer I 0.95 (0.5
II 0.90 (0.5
Psoriasis I 1.63 (0.7
II 1.41 (0.5
High medical burden I 1.80 (1.1
IIa 1.86 (1.1
aModel not adjusted for BMI as it is recorded in the medical condition. Model I – Ag
smoking and alcohol consumption. BMI, body mass index; CI, confidence interval; Goutcomes (Table 2). The relationship between lifetime
anxiety disorder and metabolic risk factors and life-
time anxiety disorders and psoriasis reached significance
following adjustment for age, BMI, SES, physical activity,
alcohol consumption and smoking status (OR 2.20, 95% CI
1.07 to 4.53, P = 0.032 and OR 2.77, 95% CI 1.00 to 7.67, P
= 0.049, respectively). There were no associations detected
between anxiety disorders and musculoskeletal disease, re-
current headaches, syncope and seizures, cardiovascular
disease, pulmonary disease, liver disorders or cancer.Discussion
Our population-based study reports associations between
mood and anxiety disorders and physical illness. Mooddds ratios for medical comorbidities in men with lifetime
disorders Anxiety disorders
5% CI P value Odds ratio 95% CI P value
3 to 2.21) 0.104 1.39 (0.72 to 2.71) 0.328
4 to 2.31) 0.092 1.70 (0.85 to 3.43) 0.135
2 to 5.12) 0.396 5.29 (1.63 to 7.14) 0.005
6 to 5.83) 0.321 5.54 (1.64 to 18.64) 0.006
5 to 1.99) 0.234 1.92 (0.96 to 3.83) 0.066
3 to 2.00) 0.265 2.20 (1.07 to 4.53) 0.032
8 to 3.00) <0.001 3.84 (2.01 to 7.33) <0.001
0 to 4.47) <0.001 4.25 (2.18 to 8.26) <0.001
3 to 2.30) 0.096 2.22 (1.20 to 4.10) 0.011
1 to 2.34) 0.112 2.40 (1.28 to 4.50) 0.006
9 to 4.69) 0.007 0.63 (0.15 to 2.69) 0.537
0 to 4.96) 0.007 0.67 (0.16 to 2.89) 0.592
1 to 3.09) 0.002 1.46 (0.75 to 2.85) 0.263
8 to 3.16) 0.002 1.55 (0.78 to 3.07) 0.207
2 to 1.93) 0.292 1.93 (0.60 to 2.13) 0.708
2 to 2.01) 0.276 1.15 (0.59 to 2.25) 0.678
- - 0.95 (0.48 to 1.86) 0.874
- - 1.02 (0.51 to 2.03) 0.956
2 to 1.58) 0.725 - - -
7 to 1.79) 0.971 - - -
5 to 5.21) 0.002 - - -
4 to 5.21) 0.005 - - -
0 to 4.98) 0.003 0.97 (0.29 to 3.24) 0.964
7 to 5.83) 0.001 1.03 (0.30 to 3.46) 0.967
6 to 1.61) 0.839 1.03 (0.47 to 2.29) 0.933
2 to 1.56) 0.706 1.03 (0.46 to 2.32) 0.938
5 to 3.55) 0.219 2.44 (0.91 to 6.57) 0.076
1 to 2.91) 0.648 2.77 (1.00 to 7.67) 0.049
6 to 2.77) 0.008 2.82 (1.43 to 5.53) 0.003
9 to 2.91) 0.007 3.23 (1.61 to6.47) 0.001
e-adjusted; Model II – Fully-adjusted including: age, BMI, SES, physical activity,
ORD, gastro oesaphogeal reflux disease; SES, socioeconomic status.
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the disease groups (GORD, neurological features, such as
recurrent headaches and syncope and seizures, liver di-
sorders and pulmonary diseases in older men). Anxiety
disorders presented a different profile; thyroid disorders,
GORD, gastrointestinal disease, metabolic risk factors,
and psoriasis were more common among individuals with
anxiety disorder. Importantly, mood and anxiety disorders
were both associated with high medical burden.
Our results confirm other population-based data in-
vestigating the association between mood disorder and
GORD [60,61]. In a sample of over 60,000 participants
residing in Norway, those identified with depressive,
anxiety and comorbid symptoms, as measured by the
Hospital Anxiety and Depression Scale, had a two- to
three-fold increased risk of reflux symptoms, self-reported
severe symptoms of recurrent heartburn or acid regurgita-
tion [62]. Moreover, mood disorders have also been shown
consistently to be more prevalent in patients with GORD
in clinical practice [15,63].
Chronic headaches are high prevalence disorders, with
as many as 46% of the adult population reporting head-
aches, 11% migraines and 42% tension headaches [64].
Similar to our findings and other population-based stu-
dies [65,66], Scott et al. [24] utilising data pooled from
18 general population surveys reported those identified
with either non-comorbid depression or comorbid de-
pression and anxiety, as measured by the Composite
International Diagnostic Interview, had an age and gen-
der adjusted odds ratio of 2.5 and 4.0, respectively, for
chronic headaches.
In regard to syncope and seizures, our results support
Morgan et al. [67] who reported fainting, blackouts and
dizziness, for which there is no adequate physical ex-
planation, were associated with undiagnosed psychiatric
disorders. Depression has also been shown to co-occur
with epilepsy. Recently, the association has been viewed
according to the diathesis-stress model, with depression
resulting from the chronic stress associated with the
threat of recurring seizures, as there is little evidence
linking specific epilepsy related factors (for example,
focus site) to low mood [68].
Akin to our results, Wilhelm and colleagues [69] re-
ported an association between depression and liver pa-
thology in a population-based survey of 10,641 adults;
however, the relationship was not sustained following
adjustment for demographic and behavioural confoun-
ders including drinking behaviour. Excessive alcohol con-
sumption is known to be highly correlated with liver
disease [21]; however, the association persisted following
correction for alcohol in our study.
In our sample, only older men with a mood disorder
were at increased risk of pulmonary disease. Although
the association between asthma and mood disorder isevident across the full adult age range [23], chronic
bronchitis and emphysema are more common among
older people and most likely contribute to the different
pattern observed for older and younger men. Further-
more, pulmonary disease can be considered in stages
reflecting severity, a factor we could not explore [70].
Musculoskeletal and gastrointestinal disorders tended
to be associated with mood disorders, although we spe-
culate that the heterogeneous groupings we employed
may have diluted associations in our sample population.
Mood disorders and symptomology have previously been
shown to be associated with low BMD and subsequent
fracture, where both biological and medication related
processes are thought to play a role [71]. Similarly, mood
disorders have been shown to be associated with gastro-
intestinal disorders in both clinical and population-based
samples [72-74].
In contrast to other population-based studies, we did
not detect a relationship between mood disorders and
thyroid disorders, metabolic risk factors, cardiovascular
disease, cancer and psoriasis in this sample of men. The
link between mood disorders and cardiovascular disease,
thyroid disorders and metabolic risk factors, in particu-
lar, is well documented [22,24,30]. We hypothesize that
these results may be influenced by a healthy participant
bias, a common issue where study participants are
required to be healthy enough to attend the research
centre. Furthermore, disease grouping and data collec-
tion limited our ability to identify the degree of illness
severity (that is, severe stroke, TIA and medically con-
trolled hypertension were grouped) or time since onset
of the physical condition.
As with mood disorders, GORD and gastrointestinal
disorders were also associated with anxiety disorders.
Anxiety has been previously considered to be a non-
disease related factor that impacts negatively on quality
of life associated with GORD [75] and, as previously
discussed, is commonly observed within population-based
samples reporting GORD symptoms [62]. Furthermore,
data from the present study concur with previous studies
indicating that those with anxiety disorder have higher
rates of gastrointestinal disorders [34].
Psoriasis has been previously associated with anxiety
disorders. Harter and colleagues [34] demonstrated that
patients with a lifetime history of generalised anxiety
disorder or panic disorder reported significantly higher
lifetime prevalence rates for dermatological disorders, in-
cluding psoriasis. Why this association is seen with anxiety
disorders only in our sample population is unclear.
Thyroid disorders and metabolic risk factors have also
been associated with anxiety disorders. In our study,
anxiety was linked to a combination of the most com-
mon risk factors for metabolic disorders, such as hy-
pertension, diabetes, hypercholesterolemia and obesity,
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due to a prolonged stress response in patients with un-
treated anxiety disorder [2]. Similarly, Simon et al. [35]
reported an increased risk of thyroid disorders in pa-
tients with generalised anxiety disorder, social phobia or
panic disorder and recommended screening for thyroid
dysfunction in patients with anxiety disorders.
Our data suggest that both mood and anxiety disor-
ders are associated with overall medical burden. These
findings are consistent with previous studies showing
both depression and anxiety to be associated with an in-
creased number of somatic conditions [5,76]. It is plaus-
ible that this relationship may be due to mood and
anxiety disorders causing physiological changes, as well
as poorer self-care and treatment adherence, which in
turn increase medical burden [36]. On the other hand,
an increased physical burden, causing functional impair-
ment, may result in the development of an anxiety and/
or mood disorder, which have been shown to have a
negative impact on clinical outcomes [77].
A major strength of our study is that the sample popu-
lation spans the full adult age range, in contrast to previ-
ous studies that have mainly focused on older patients.
An age interaction was only evident when exploring the
association between mood disorders and pulmonary dis-
ease; thus the relationship between mental illness and
each of the physical conditions was consistent across all
ages. Further strengths of the study include the measure-
ment of mood and anxiety disorders, diagnoses were made
utilising semi-structured clinical interviews (SCID-IV), a
gold standard tool, and the consideration of several
possible confounding factors. However, our observations
must be considered with caution. Ascertaining medical
conditions by a self-report checklist may be compromised
by imperfect recall and response bias error. Although
many of these disorders were based on self-report of a
physician’s diagnosis, which have been demonstrated to
generally agree with medical record data [78], where pos-
sible this was confirmed by medical records, medication
use or clinical data. The cross-sectional nature of the
study does not allow verification of a cause-effect relation-
ship between mental and physical illness, longitudinal
studies are needed to determine the directionality of this
relationship. Finally, we were unable to make a distinction
between diseases with an episodic course and those with
ongoing symptoms, which may impact differently on psy-
chological status.
Conclusion
Our study provides further population-based evidence
supporting the link between mental and physical illness
in men. Recognising the link between these illnesses is
important in order to manage the development of mood
and anxiety disorders in response to a medical condition,or the presence of physical pathologies due to predis-
posing psychiatric disorders. Integrating treatment ap-
proaches and monitoring comorbidity of mental and
physical illnesses is likely to improve disease course and
outcome as well as enhance patients’ functional and
health status, potentially reducing healthcare utilisation.
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